BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37065178)

  • 1. Immunotherapy and Immune Infiltration in Patients with Clear Cell Renal Cell Carcinoma: A Comprehensive Analysis.
    Hou L; Liu X
    Genet Res (Camb); 2023; 2023():3898610. PubMed ID: 37065178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel nine-microRNA-based model to improve prognosis prediction of renal cell carcinoma.
    Xu C; Zeng H; Fan J; Huang W; Yu X; Li S; Wang F; Long X
    BMC Cancer; 2022 Mar; 22(1):264. PubMed ID: 35279104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A risk signature based on necroptotic-process-related genes predicts prognosis and immune therapy response in kidney cell carcinoma.
    Li J; Liu X; Qi Y; Liu Y; Du E; Zhang Z
    Front Immunol; 2022; 13():922929. PubMed ID: 36189275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Establishment of a mutation prediction model for evaluating the efficacy of immunotherapy in renal carcinoma].
    Qin CP; Song YX; Ding MT; Wang F; Lin JX; Yang WB; DU YQ; Li Q; Liu SJ; Xu T
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Aug; 54(4):663-668. PubMed ID: 35950389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrative bioinformatics analysis of a prognostic index and immunotherapeutic targets in renal cell carcinoma.
    Tao H; Li Z; Mei Y; Li X; Lou H; Dong L; Zhou L
    Int Immunopharmacol; 2020 Oct; 87():106832. PubMed ID: 32738597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutathione peroxidase family and survival prognosis in patients with renal cell carcinoma.
    Li J; Huo S; Zhang R; Shi C; Sun N; Liu Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 May; 47(5):562-572. PubMed ID: 35753726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis.
    Wang Y; Yan K; Lin J; Wang J; Zheng Z; Li X; Hua Z; Bu Y; Shi J; Sun S; Li X; Liu Y; Bi J
    Aging (Albany NY); 2020 Nov; 12(21):21854-21873. PubMed ID: 33154194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of an immunogenic cell death-related gene signature predicts survival and sensitivity to immunotherapy in clear cell renal carcinoma.
    Zhou S; Lu Y; Chen Y; Gan W
    Sci Rep; 2023 Mar; 13(1):4449. PubMed ID: 36932108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
    Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
    Front Immunol; 2022; 13():933241. PubMed ID: 36211378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma.
    Tripathi A; Lin E; Xie W; Flaifel A; Steinharter JA; Stern Gatof EN; Bouchard G; Fleischer JH; Martinez-Chanza N; Gray C; Mantia C; Thompson L; Wei XX; Giannakis M; McGregor BA; Choueiri TK; Agarwal N; McDermott DF; Signoretti S; Harshman LC
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33177176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma.
    Song J; Liu YD; Su J; Yuan D; Sun F; Zhu J
    J Cell Physiol; 2019 Dec; 234(12):22753-22764. PubMed ID: 31140607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.
    Wu Z; Shen Y; Fan D; Liu J; Chen D; Wang K; Xu X
    Int Immunopharmacol; 2021 Jan; 90():107119. PubMed ID: 33243605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics.
    Zhang S; Xu X; Wang Y; Zhu Y; Wang J; Wang H; Guo J
    Ann Clin Lab Sci; 2021 Sep; 51(5):597-608. PubMed ID: 34686501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
    Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
    Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of exosome-related genes risk model in kidney cell carcinoma predicts prognosis and immune therapy response.
    Gao C; Huang W; Su Q; Li J; Wang W; Qi Y; Du E; Zhang Z
    Aging (Albany NY); 2024 May; 16(9):7622-7646. PubMed ID: 38728235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
    Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
    Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
    Front Immunol; 2022; 13():890150. PubMed ID: 35686121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which
    Xu K; Zhang Y; Yan Z; Wang Y; Li Y; Qiu Q; Du Y; Chen Z; Liu X
    Front Immunol; 2023; 14():1205250. PubMed ID: 37426643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.